Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Arcturus Therapeutics Inc.

www.arcturusrx.com

Latest From Arcturus Therapeutics Inc.

Arcturus's Differentiated RNA Technology Faces First Clinical Test In 2017

Emerging Company Profile: San Diego-based Arcturus Therapeutics has developed technology for the targeted delivery of RNA therapeutics, which Johnson & Johnson's Janssen subsidiary will evaluate for the first time in humans in a clinical trial starting as early as this year for the partners' hepatitis B drug candidate.

Commercial StartUps and SMEs

J&J’s Comprehensive Approach To Finding A ‘Functional Cure’ For HBV

Capsid assembly modulation, small-interfering RNA, a TLR7 agonist and a DNA-based vaccine are some of the components of the pharma’s strategy for bringing about significant advancement in hepatitis B therapy.

Business Strategies Research and Development Strategies

ContraVir Hopes To Establish Backbone For Hepatitis B Combo Therapy

Two deals have resulted in the formerly shingles-focused biotech beginning to build an HBV pipeline and look ahead to therapeutic advances similar to those seen in HIV and hepatitis C. But the New Jersey biotech will be competing with some deep-pocketed competitors in the space.

Commercial Research & Development

J&J Looks To Get Ahead In Hep B With Combination Strategy

Deal with China's Chia Tai Tianqing Pharmaceutical Group is the latest development in J&J's efforts to develop a curative regimen for hepatitis B. The earlier acquisitions of Alios and Novira and a partnership with Arcturus also factor into the pharma's strategy to attack the virus with a variety of modalities.

BioPharmaceutical United States
See All

Company Information

  • Industry
  • Biotechnology
    • Antisense, Oligonucleotides
    • Large Molecule
    • Nanotechnology, Chips, etc.
  • Pharmaceuticals
    • Drug Delivery
      • Macromolecule
  • Therapeutic Areas
  • Respiratory, Pulmonary
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Company Type
  • Start-Up
  • Parent & Subsidiaries
  • Arcturus Therapeutics Inc.
  • Senior Management
  • Joseph E Payne, Pres. & CEO
    Pad Chivukula, PhD, CSO & COO
  • Contact Info
  • Arcturus Therapeutics Inc.
    Phone: (858) 900-2660
    10628 Science Center Dr., Ste. 200
    San Diego, CA 92121
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register